Stock Screener App

Gratuito -

Installare

3.67

3.55% -0.135

after-market

Dopo l'orario di chiusura: 3.67

Titan Pharmaceuticals Inc De (TTNP)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Frazionamento azionario

Titan Pharmaceuticals Inc De Borsa (TTNP) Ultime notizie

Elite Pharmaceuticals Revenue Surges 33% to $18.9M, Operating Profit Jumps 84% | ELTP Stock News - StockTitan

Meiji Seika Pharma Invests in ARCALIS to Boost Japan's mRNA Vaccine Production | ARCT Stock News - StockTitan

Virpax Pharmaceuticals Raises $5M in Public Offering to Advance Pain Management Drug | VRPX Stock News - StockTitan

Universe Pharmaceuticals Announces 15:1 Reverse Stock Split Amid NASDAQ Concerns | UPC Stock News - StockTitan

Acurx Pharma Q3: New Patent Win & Trial Progress Despite Cash Decline to $5.8M | ACXP Stock News - StockTitan

Syros Pharma Stock Alert: Phase 3 Trial Fails, Loan Default Triggered | SYRS Stock News - StockTitan

Longboard Pharma Launches Groundbreaking Phase 3 Trial for Rare Epilepsy Treatment | LBPH Stock News - StockTitan

CERo's Cancer Drug Shows Breakthrough: Kills Ovarian Cancer Without Toxicity in Key Study | CERO Stock News - StockTitan

Hepion & Pharma Two B Merger Advances: SEC Approves Key Registration for $HEPA Deal | HEPA Stock News - StockTitan

NRx Pharmaceuticals Sets Q3 2024 Earnings Call for November 14 | NRXP Stock News - StockTitan

NovaBay Pharmaceuticals Reports Third Quarter 2024 Financial Results - StockTitan

Ionis Pharmaceuticals to Present at 6 Major Healthcare Investor Conferences | IONS Stock News - StockTitan

Elite Pharmaceuticals (ELTP) to Host Q2 FY2025 Earnings Call on November 15 | ELTP Stock News - StockTitan

Madrigal Pharmaceuticals to Present at Three Major Healthcare Investor Conferences | MDGL Stock News - StockTitan

Acumen Pharmaceuticals to Report Third Quarter Results on Nov. 12, 2024 - StockTitan

InMed Gets Nasdaq Lifeline: 20:1 Share Consolidation Plan to Avoid Delisting | INM Stock News - StockTitan

Bionoid Pharma Unveils 5-Year AI-Powered Growth Strategy, Targets 15% EBITDA | BINP Stock News - StockTitan

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences - StockTitan

Dario Expands Pharma Collaborations with Global Pharma Leader to Enhance User Engagement - StockTitan

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences - StockTitan

Conduit Pharmaceuticals Announces Debt Restructuring and Additional Notes - StockTitan

Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split - StockTitan

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan

Universe Pharmaceuticals INC Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency - StockTitan

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Signing of a Letter of Intent to Acquire its First Florida Interventional Psychiatry Clinics - StockTitan

Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules - StockTitan

Shuttle Pharmaceuticals to Present at the 2024 ThinkEquity Conference on Wednesday, October 30, 2024 - StockTitan

Scilex Holding Company sets November 7, 2024 as the Record Date for a Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary - StockTitan

Ironwood Pharmaceuticals to Host Third Quarter 2024 Investor Update Call - StockTitan

Marinus Pharmaceuticals Announces Topline Results From Phase 3 TrustTSC Trial of Oral Ganaxolone in Tuberous Sclerosis Complex and Commences Process to Explore Strategic Alternatives - StockTitan

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) and HOPE Therapeutics, Inc. Announce Participation at the ThinkEquity Conference October 30, 2024 - StockTitan

Apellis Pharmaceuticals to Host Conference Call on November 5, 2024, to Discuss Third Quarter 2024 Financial Results - StockTitan

Madrigal Pharmaceuticals to Release Third-Quarter 2024 Financial Results and Host Webcast on October 31, 2024 - StockTitan

KalVista Pharmaceuticals to Present Data at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) - StockTitan

Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 6, 2024 - StockTitan

Kintara Therapeutics Announces 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences - StockTitan

Acurx Pharmaceuticals to Discuss Third Quarter 2024 Financial Results on November 13, 2024 - StockTitan

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - StockTitan

Viatris Announces Exclusive Licensing Agreement with Lexicon Pharmaceuticals for Sotagliflozin in all Markets Outside of the U.S. and Europe - StockTitan

C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D. - StockTitan

Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Topline Results from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on October 17, 2024 - StockTitan

Lipella Pharmaceuticals Announces U.S. Patent Allowance for Innovative Liposomal Drug Delivery Platform - StockTitan

New to the Street Resigns Acurx Pharmaceuticals, Inc. to Multi-Platform Media Series Featuring Broadcast Television, Earned Media, and Outdoor Advertising Support - StockTitan

Vanda Pharmaceuticals Confirms Receipt of Economically Identical Unsolicited, Non-Binding Proposal from Cycle Group Holdings Ltd. - StockTitan

Cycle Pharmaceuticals Reaffirms All-Cash Proposal to Acquire Vanda Pharmaceuticals for $8.00 Per Share - StockTitan

Opioids Agonist Drugs Market Research Report 2024 -Purdue Pharma, Titan pharmaceuticals, Boehringer Ingelheim, Janssen P – IndiaPolitics.com - IndiaPolitics.com

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan

Supernus Pharmaceuticals to Host Webcast to Review Open-Label Phase 2a Study of SPN-820 for the Treatment of Major Depressive Disorder - StockTitan

Elite Pharmaceuticals' Generic Adderall(R) Receives Marketing Approval from the Israeli Ministry of Health - StockTitan

Crinetics Pharmaceuticals Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan

CNS Pharmaceuticals Participates in Virtual Investor KOL Connect Segment - StockTitan

Eupraxia Pharmaceuticals to Present at United European Gastroenterology Week 2024 - StockTitan

Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium - StockTitan

Marinus Pharmaceuticals Announces Podium and Poster Presentations at the Neurocritical Care Society 2024 Annual Meeting - StockTitan

Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock - StockTitan

Joint Venture Company Established for Incubation of Early Drug Discovery Programs; Investment from Takeda, Astellas and Sumitomo Mitsui Banking - StockTitan

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - StockTitan

Rhythm Pharmaceuticals Announces New Employment Inducement Grants - StockTitan

CNS Pharmaceuticals to Participate in the 2024 Healthcare Virtual Summit Presented by Maxim Group LLC - StockTitan

China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency - StockTitan

Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt - StockTitan

SMMT

$18.98

3.66%

INCY

$76.97

1.45%

MRNA

$39.51

7.22%

UTHR

$359.21

1.11%

BGNE

$187.69

0.81%

BNTX

$101.87

2.16%

Apri su Yahoo | Apri su Google | Aperto in Finviz | Apri in MarketWatch | Aperto a EDGAR | Aperto su Reuters